Literature DB >> 27182215

Liver Transplant in Patients With Primary Sclerosing Cholangitis.

David S Goldberg1.   

Abstract

Entities:  

Year:  2016        PMID： 27182215      PMCID： PMC4865774     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.

Authors:  David Goldberg; Benjamin French; Arwin Thomasson; K Rajender Reddy; Scott D Halpern
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

2.  Superior survival using living donors and donor-recipient matching using a novel living donor risk index.

Authors:  David S Goldberg; Benjamin French; Peter L Abt; Kim Olthoff; Abraham Shaked
Journal:  Hepatology       Date:  2014-10-02       Impact factor: 17.425

3.  ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; M Edwyn Harrison
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

4.  Current trends in living donor liver transplantation for primary sclerosing cholangitis.

Authors:  David Seth Goldberg; Benjamin French; Arwin Thomasson; K Rajender Reddy; Scott D Halpern
Journal:  Transplantation       Date:  2011-05-27       Impact factor: 4.939

Review 5.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126
  5 in total
  2 in total

1.  Neonatal cholestasis due to primary sclerosing cholangitis.

Authors:  Naman Sadanand Shetty; Ira Shah
Journal:  J Family Med Prim Care       Date:  2016 Oct-Dec

2.  Primary sclerosing cholangitis with increased immunoglobulin G4 levels: A case report.

Authors:  Qing-Ling Chen; Rui Zhong; Xiao-Xue Zhang; Li-Na Feng; Xiao-Yu Wen; Qing-Long Jin
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.